Effect of polycyclic aromatic hydrocarbons on the elimination kinetics of pyrene and the urinary excretion profile of 1-hydroxypyrene in the rat.
Pyrene was chosen as a noncarcinogen model of polycyclic aromatic hydrocarbons (PAHs). Groups of male Wistar rats were dosed with pyrene and with mixture of pyrene and fluoranthene, pyrene and benz[a]anthracene, or pyrene, fluoranthene, and benz[a]anthracene at 20 mg/kg by intravenous or oral routes. Blood samples were taken at 0.25, 0.5, 1, 2, 3, 4, and 5 h after administration. The concentration of pyrene was determined by gas chromatography. The toxicokinetic parameters for pyrene were determined from the time course of blood concentration. A significant increase in the bioavailability of pyrene after treatment with other PAHs was observed. Urinary 1-hydroxypyrene excretion was analyzed after pretreatment with acenaphthene, naphthalene, chrysene, phenanthrene, benz[a]anthracene, and benzo[a]pyrene. The urine from rats was collected for 3 d and the concentration of 1-hydroxypyrene was determined using high-performance liquid chromatography (HPLC). Most compounds examined caused a decrease in the urinary excretion of the metabolite of pyrene.
Lipniak-Gawlik
M
M
Department of Toxicology, Collegium Medicum, Jagiellonian University, Cracow, Poland. mfgawlik@cyf-kr.edu.pl
D000284:Administration, Oral; D000818:Animals; D001822:Body Burden; D006841:Hydrocarbons, Aromatic / Q000009:adverse effects / Q000493:pharmacokinetics* / Q000494:pharmacology; D006844:Hydrocarbons, Cyclic / Q000009:adverse effects / Q000493:pharmacokinetics* / Q000494:pharmacology; D007275:Injections, Intravenous; D007700:Kinetics; D008297:Male; D009153:Mutagens / Q000009:adverse effects / Q000493:pharmacokinetics*; D011721:Pyrenes / Q000009:adverse effects / Q000493:pharmacokinetics*; D051381:Rats; D017208:Rats, Wistar
D006841:Hydrocarbons, Aromatic; D006844:Hydrocarbons, Cyclic; D009153:Mutagens; D011721:Pyrenes; C030984:pyrene; C033146:1-hydroxypyrene